PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

Study Evaluating SKI-606 (Bosutinib) In Subjects With Breast Cancer

Phase 2

Completed

Conditions: Breast Neoplasms
Neoplasm Metastasis

Interventions: Drug: SKI-606 (Bosutinib)

First Posted Date: 2006-04-27

Last Posted Date: 2013-01-31

Lead Sponsor: Pfizer

Target Recruit Count: 75

Registration Number: NCT00319254

Locations: 🇺🇦
Pfizer Investigational Site, Uzhgorod, Ukraine

Safety and Efficacy Study of MRE0094 to Treat Large, Single or Multiple, Chronic, Neuropathic, Diabetic Foot Ulcers

Phase 2

Terminated

Conditions: Foot Ulcer, Diabetic
Diabetes Complications

Interventions: Drug: MRE0094
Drug: Vehicle gel

First Posted Date: 2006-04-26

Last Posted Date: 2012-06-01

Lead Sponsor: Pfizer

Target Recruit Count: 16

Registration Number: NCT00318214

Locations: 🇺🇸
Associated Foot & Ankle Specialists, LLC, Phoenix, Arizona, United States
🇺🇸
Innovative Medical Technologies, Los Angeles, California, United States
🇺🇸
University of Miami, Miami, Florida, United States

and more 16 locations

A Single Dose Study to Evaluate the PK-PD Response and Safety of PHA-794428 in Children With Growth Hormone Deficiency

Phase 2

Terminated

Conditions: Growth Hormone Deficiency

First Posted Date: 2006-04-17

Last Posted Date: 2011-05-16

Lead Sponsor: Pfizer

Target Recruit Count: 32

Registration Number: NCT00314938

Locations: 🇬🇧
Pfizer Investigational Site, Cardiff, United Kingdom

Study Evaluating PD-0299685 for the Treatment of Vasomotor Symptoms (Hot Flashes / Flushes) Associated With Menopause

Phase 2

Completed

Conditions: Hot Flashes

First Posted Date: 2006-04-17

Last Posted Date: 2011-03-16

Lead Sponsor: Pfizer

Target Recruit Count: 527

Registration Number: NCT00314964

Locations: 🇪🇸
Pfizer Investigational Site, Valencia, Spain

Randomized Ph 2 Trial Of Paclitaxel/Carboplatin /Bevacizumab + PF-3512676 And P/C/B Alone In Advanced Nonsquamous NSCLC

Phase 2

Terminated

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: paclitaxel + carboplatin + bevacizumab
Drug: carboplatin + paclitaxel + bevacizumab + PF-3512676

First Posted Date: 2006-04-12

Last Posted Date: 2009-09-28

Lead Sponsor: Pfizer

Target Recruit Count: 23

Registration Number: NCT00313768

Locations: 🇺🇸
Pfizer Investigational Site, San Marcos, Texas, United States

Study of CP-751,871 in Combination With Docetaxel and Prednisone in Patients With Hormone Insensitive Prostate Cancer (HRPC)

Phase 2

Completed

Conditions: Prostatic Neoplasms

Interventions: Drug: CP-751,871
Drug: docetaxel
Drug: prednisone

First Posted Date: 2006-04-12

Last Posted Date: 2013-04-11

Lead Sponsor: Pfizer

Target Recruit Count: 204

Registration Number: NCT00313781

Locations: 🇬🇧
Pfizer Investigational Site, Guildford, United Kingdom

Safety and Efficacy Study of MRE0094 to Treat Chronic, Neuropathic, Diabetic Foot Ulcers

Phase 2

Completed

Conditions: Foot Ulcer, Diabetic
Diabetes Complications

First Posted Date: 2006-04-10

Last Posted Date: 2012-06-01

Lead Sponsor: Pfizer

Target Recruit Count: 322

Registration Number: NCT00312364

Locations: 🇺🇸
Cleveland Clinic Foundation, Cleveland, Ohio, United States
🇺🇸
UCSD Wound Treatment and Research Center, San Diego, California, United States
🇺🇸
Institute for Advanced Wound Care, Montgomery, Alabama, United States

and more 60 locations

Thorough QT Study of Nelfinavir

Phase 4

Completed

Conditions: Healthy Volunteers

First Posted Date: 2006-04-07

Last Posted Date: 2009-04-10

Lead Sponsor: Pfizer

Target Recruit Count: 68

Registration Number: NCT00312182

Locations: 🇸🇬
Pfizer Investigational Site, Singapore, Singapore

Study Comparing Effect On Carotid Atherosclerosis Following Conversion From Tacrolimus To Sirolimus Post-Transplant In Kidney Transplant Patients

Phase 3

Terminated

Conditions: Atherosclerosis
Kidney Failure

Interventions: Drug: tacrolimus
Drug: sirolimus
Drug: mycophenolate mofetil
Drug: prednisone

First Posted Date: 2006-04-05

Last Posted Date: 2013-09-23

Lead Sponsor: Pfizer

Target Recruit Count: 72

Registration Number: NCT00311311

Locations: 🇨🇦
Pfizer Investigational Site, Montreal, Quebec, Canada

A Study To Evaluate The Dose Response And Safety Of PHA-794428 In Adults With Growth Hormone Deficiency

Phase 2

Terminated

Conditions: Growth Hormone Deficiency

First Posted Date: 2006-03-29

Last Posted Date: 2011-05-18

Lead Sponsor: Pfizer

Target Recruit Count: 136

Registration Number: NCT00308464

Locations: 🇬🇧
Pfizer Investigational Site, Oxford, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy